Treatment outcomes in patients with febrile neutropenia progressing to a critical condition

Purpose. To determine the spectrum of febrile neutropenia (FN) complications resulting in critical conditions in patients receiving anti-tumor therapy, and to assess the immediate results of intensive care. Materials and Methods. This was an observational single-center study with 103 patients, who developed postcytostatic therapy febrile neutropenia progressing to a critical condition. Eligibility criteria included: anti-tumor therapy received within 29 days prior to admission to the Department of Critical and Intensive Care (DCIC) and complicated by FN; critical illness existing on admission or developing within 24 hours of admission to the DCIC; age over 16 years. Recorded data included demographics, vital signs, and test results obtained during the first 24 hours of treatment, which were required to evaluate the severity of adverse events in accordance with the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0), the Systemic Inflammatory Response Syndrome (SIRS) criteria and the Sequential Organ Failure Assessment (SOFA) score; 30-day mortality and the subsequent anti-tumor therapy start date...